# Adjuvant nivolumab versus ipilimumab in resected stage IIIB–C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial

**Type:** Papers  
**Canonical URL:** https://scholariq.org/papers/adjuvant-nivolumab-versus-ipilimumab-in-resected-stage-iiib-c-and-stage-iv/

## Facts

| Field | Value |
| --- | --- |
| Author Names | Paolo A. Ascierto,Michele Del Vecchio,Mario Mandalà,Helen Gogas,Ana Arance,Stéphane Dalle,C. Lance Cowey,Michael Schenker,Jean-Jacques Grob,Vanna Chiarion‐Sileni,Iván Márquez‐Rodas,Marcus O. Butler,Michele Maio,Mark R. Middleton,Luis de la Cruz‐Merino,Petr Arenberger,Victoria Atkinson,Andrew Hill,Leslie A. Fecher,Michael Millward,Nikhil I. Khushalani,Paola Queirolo,Maurice Lobo,Veerle de Pril,John T. Loffredo,James Larkin,Jeffrey S. Weber |
| Citations | 528 |
| DOI | 10.1016/s1470-2045(20)30494-0 |
| Fields | Biochemistry, Genetics and Molecular Biology,Medicine |
| Open Access | false |
| OA Status | closed |
| OpenAlex ID | https://openalex.org/W3087697977 |
| PMID | 32961119 |
| Type | article |
| Year | 2020 |

## Paper authors

- [Leslie A. Fecher](https://scholariq.org/researchers/leslie-a-fecher/)

## Paper journal

- [The Lancet Oncology](https://scholariq.org/journals/the-lancet-oncology/)

## Paper primary topic

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)

## Paper topics

- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cutaneous Melanoma Detection and Management](https://scholariq.org/topics/cutaneous-melanoma-detection-and-management/)
- [Melanoma and MAPK Pathways](https://scholariq.org/topics/melanoma-and-mapk-pathways/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.